Artículo
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanoma
Autor/es | Dreno, Brigitte
Ascierto, Paolo A. Atkinson, Victoria Liszkay, Gabriella Maio, Michele Mandala, Mario Cruz Merino, Luis de la Ribas, Antoni |
Departamento | Universidad de Sevilla. Departamento de Medicina |
Fecha de publicación | 2018 |
Fecha de depósito | 2024-03-11 |
Publicado en |
|
Resumen | Background: In the coBRIM study, cobimetinib plus vemurafenib (C þ V) significantly improved survival outcomes vs placebo and
vemurafenib (P þ V) in patients with advanced/metastatic BRAFV600-mutated melanoma. An analysis ... Background: In the coBRIM study, cobimetinib plus vemurafenib (C þ V) significantly improved survival outcomes vs placebo and vemurafenib (P þ V) in patients with advanced/metastatic BRAFV600-mutated melanoma. An analysis of health-related quality of life (HRQOL) from coBRIM is reported. Methods: Patients completing the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30) at baseline and X1 time point thereafter constituted the analysis population. Change from baseline X10 points was considered clinically meaningful. Results: Mean baseline scores for all QLQ-C30 domains were similar between arms. Most on-treatment scores for QLQ-C30 domains were also comparable between arms. A transient deterioration in role function in cycle 1 day 15 (C1D15; -14.7 points) in the Pþ V arm and improvement in insomnia in the Cþ V arm at C2D15 (-12.4 points) was observed. Among patients who experienced a X10-point change from baseline (responders), between-group differences were greatest for insomnia (16%), social functioning (10%), fatigue (9%) and pain (7%), all favouring C þ V. Diarrhoea, photosensitivity reaction, pyrexia, and rash did not meaningfully affect global health status (GHS). Serous retinopathy was associated with a transient decrease in GHS at C1D15 assessment. Conclusions: In patients with advanced/metastatic BRAFV600-mutated melanoma, treatment with C þ V maintained HRQOL compared with P þ V, with superior efficacy. |
Cita | Dreno, B., Ascierto, P.A., Atkinson, V., Liszkay, G., Maio, M., Mandala, M.,...,Ribas, A. (2018). Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanoma. British journal of cancer, 118 (6), 777-784. https://doi.org/10.1038/bjc.2017.488. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Health-related quality.pdf | 497.0Kb | [PDF] | Ver/ | |